title: [Toxic effect of immunosuppression agent Everolimus on insuloma cells and pancreatic islets of SD rat].
abstract: OBJECTIVE
  To investigate the effect of immunosuppression agent Everolimus on the viability and function of insuloma cells (INS-1) and pancreatic islet cells cultured in vitro.
  
  
  METHODS
  INS-1 cells and islets were treated with a series of concentrations of immunosuppression agents (Everolimus, Cyclosporin A, Sirolimus and Mycophenolate Mofetil). The viability of INS-1 cells and rat pancreatic islets were determined with MTT and the function of INS-1 cells and rat pancreatic islets was evaluated with Glucose-stimulated insulin secretion assay.
  
  
  RESULTS
  Above the clinical blood concentration, the inhibition rate of islet cell proliferation in the high concentration group of Everolimus and Sirolimus was significantly lower than that of Cyclosporin A and Mycophenolate Mofetil group (P < 0.05); Everolimus in the blood drug level, like other immunosuppressive agents, can inhibit the function of insulin secretion, and the stimulation index of each group was no significant difference.
  
  
  CONCLUSIONS
  Compared to Mycophenolate Mofetil and Cyclosporin A, Everilimus and Sirolimus demonstrate lower toxicity effect on INS-1 cells and rat pancreatic islets in vitro and Everolimus is expected as a new type of immunosuppressive agent used in clinical islet transplantation.
authors.affiliation: Key Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Jin
authors.forename: Cong
authors.initials: C
authors.lastname: Cong
authors.forename: Yu
authors.initials: Y
authors.lastname: Yuan
authors.forename: Gang
authors.initials: G
authors.lastname: Mai
authors.forename: Ling-Ling
authors.initials: LL
authors.lastname: Wei
authors.forename: You-Nan
authors.initials: YN
authors.lastname: Chen
authors.forename: Jing-Qiu
authors.initials: JQ
authors.lastname: Cheng
authors.forename: Yan-Rong
authors.initials: YR
authors.lastname: Lu
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival; D002478:Cells, Cultured; D016572:Cyclosporine / Q000009:adverse effects / Q000494:pharmacology; D000068338:Everolimus; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007340:Insulinoma / Q000473:pathology*; D007515:Islets of Langerhans / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D010190:Pancreatic Neoplasms / Q000473:pathology; D051381:Rats; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D007166:Immunosuppressive Agents; D007328:Insulin; D016572:Cyclosporine; D000068338:Everolimus; D009173:Mycophenolic Acid; D020123:Sirolimus